Publications by authors named "Rod A Humerickhouse"

Claim this Profile
U
Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy.
Anthony R Mato, William G Wierda, Matthew S Davids, Bruce D Cheson, Steven E Coutre, Rod A Humerickhouse

Haematologica· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma.
Matthew S Davids, Gottfried von Keudell, Craig A Portell, Jonathon B Cohen, David C Fisher, Rod A Humerickhouse

J Clin Oncol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.
Steven Coutre, Michael Choi, Richard R Furman, Herbert Eradat, Leonard Heffner, Rod A Humerickhouse

Blood· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
Jeffrey A Jones, Anthony R Mato, William G Wierda, Matthew S Davids, Michael Choi, Rod A Humerickhouse

Lancet Oncol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.
Kevin J Freise, Aksana K Jones, Rajeev M Menon, Maria E Verdugo, Rod A Humerickhouse

Hematol Oncol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.
Kevin J Freise, Aksana K Jones, Doerthe Eckert, Sven Mensing, Shekman L Wong, Rod A Humerickhouse

Clin Pharmacokinet· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.
Ahmed Hamed Salem, Suresh K Agarwal, Martin Dunbar, Sari L Heitner Enschede, Rod A Humerickhouse

J Clin Pharmacol· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.
Matthew S Davids, Andrew W Roberts, John F Seymour, John M Pagel, Brad S Kahl, Rod A Humerickhouse

J Clin Oncol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
John F Seymour, Shuo Ma, Danielle M Brander, Michael Y Choi, Jacqueline Barrientos, Rod A Humerickhouse

Lancet Oncol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments.
Suresh K Agarwal, Courtney D DiNardo, Jalaja Potluri, Martin Dunbar, Hagop M Kantarjian, Rod A Humerickhouse

Clin Ther· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis.
Aksana K Jones, Kevin J Freise, Suresh K Agarwal, Rod A Humerickhouse, Shekman L Wong

AAPS J· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
Andrew W Roberts, Matthew S Davids, John M Pagel, Brad S Kahl, Soham D Puvvada, Rod A Humerickhouse

N Engl J Med· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.
Andrew J Souers, Joel D Leverson, Erwin R Boghaert, Scott L Ackler, Nathaniel D Catron, Rod A Humerickhouse

Nat Med· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.
Charles M Rudin, Christine L Hann, Edward B Garon, Moacyr Ribeiro de Oliveira, Philip D Bonomi, Rod A Humerickhouse

Clin Cancer Res· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparative study of dynamic contrast-enhanced MRI parameters as biomarkers for anti-angiogenic drug therapy.
Tong San Koh, Choon Hua Thng, Septian Hartono, Bee Choo Tai, Helmut Rumpel, Rod A Humerickhouse

NMR Biomed· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.
Wyndham H Wilson, Owen A O'Connor, Myron S Czuczman, Ann S LaCasce, John F Gerecitano, Rod A Humerickhouse

Lancet Oncol· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 trial of 2 dose schedules of ABT-510, an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with advanced cancer.
Michael S Gordon, David Mendelson, Robert Carr, Raymond A Knight, Rod A Humerickhouse

Cancer· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma.
Laurence H Baker, Eric K Rowinsky, David Mendelson, Rod A Humerickhouse, Raymond A Knight

J Clin Oncol· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma.
Scot Ebbinghaus, Maha Hussain, Nizar Tannir, Michael Gordon, Apurva A Desai, Rod A Humerickhouse

Clin Cancer Res· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigation of the immunogenicity of a protein drug using equilibrium dialysis and liquid chromatography tandem mass spectrometry detection.
Qin C Ji, Ramona Rodila, Sherry J Morgan, Rod A Humerickhouse, Tawakol A El-Shourbagy

Anal Chem· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer.
Ronald Hoekstra, Filip Y F L de Vos, Ferry A L M Eskens, Jourik A Gietema, Ate van der Gaast, Rod A Humerickhouse

J Clin Oncol· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer.
Bernard A Zonnenberg, Gerard Groenewegen, Todd J Janus, Terri W Leahy, Rod A Humerickhouse

Clin Cancer Res· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial.
Michael A Carducci, Robert J Padley, Jurgen Breul, Nicholas J Vogelzang, Bernard A Zonnenberg, Rod A Humerickhouse

J Clin Oncol· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis